FDA panel recommends new safety information on AstraZeneca Onglyza
The FDA panel has taken a stand on DPP-4 inhibitors, which includes AstraZeneca’s Onglyza (saxagliptin) and Takeda’s Nesina (alogliptin), can be associated with increased risk of cardiac failure. Way back in...